Takeda presents postive pivotal data for replacement ARB
This article was originally published in Scrip
Executive Summary
Takeda has presented positive data from seven pivotal trials of azilsartan medoxomil, an angiotensin II receptor blocker (ARB) that the company hopes could replace lost sales of its current blockbuster ARB, Atacand/Blopress (candesartan), which starts to lose patent protection next year.